Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05802329 · ClinicalTrials.gov registry record · Phase 1
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
A Phase 1 study of Diabetic Macular Edema and Center Involved Diabetic Macular Edema, sponsored by Ocugen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 5
- Study locations
NCT05802329: Recruiting Phase 1 study of Diabetic Macular Edema and Center Involved Diabetic Macular Edema, sponsored by Ocugen.
NCT05802329 is a Phase 1 study of Diabetic Macular Edema and Center Involved Diabetic Macular Edema that is actively recruiting participants, run by Ocugen. The registered enrollment target is 24 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05802329, a Phase 1 study of Diabetic Macular Edema and Center Involved Diabetic Macular Edema, is actively recruiting participants, sponsored by Ocugen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema
Primary Outcome
Counts, frequencies and percentages of SDAEs.
Conditions Studied
Interventions
- DRUG OCU200
Study Locations (5)
Texas
- Retina Consultants of Texas Research Centers - Bellaire
- Retina Consultants of America - Southlake
Florida
- Advanced Research LLC - Deerfield Beach
Pennsylvania
- Erie Retina Research, LLC - Erie
Wisconsin
- Gundersen Health System - La Crosse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-01-13 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 1 |
What NCT05802329 shows while recruiting
NCT05802329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which OCU200 is the first listed.
NCT05802329 lists 5 locations in 4 states (Texas, Florida, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT05802329 about?
NCT05802329 is a clinical study titled "Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)". A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema
What is the current status of trial NCT05802329?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-01-13. Estimated completion is 2026-07-31.
What conditions does trial NCT05802329 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Center Involved Diabetic Macular Edema.
What interventions are being tested in trial NCT05802329?
The interventions under investigation include: OCU200 (DRUG).
Who is sponsoring clinical trial NCT05802329?
This trial is sponsored by Ocugen, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05802329 being conducted?
This trial has 5 study locations across Florida, Pennsylvania, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05802329's enrollment target sits among peer trials
24 51st of 63 higher than 13 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI